1869057-83-9
Chemical Structure
Firmonertinib
Synonym(s): Alflutinib; Furmonertinib; AST2818
- CAS No.: 1869057-83-9
- Formula:C28H31F3N8O2
- Molecular Weight:568.59
IUPAC Name: N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)acrylamide
InChIKey: GHKOONMJXNWOIW-UHFFFAOYSA-N
SMILES: C=CC(NC1=CC(NC2=NC=CC(C3=CN(C)C4=C3C=CC=C4)=N2)=C(OCC(F)(F)F)N=C1N(CCN(C)C)C)=O
Biological Activity: Firmonertinib (Alflutinib; Furmonertinib) is an orally active, mutant-selective, and highly brain penetrant EGFR inhibitor. Firmonertinib inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Firmonertinib has the potential for the research of cancer diseases, especially advanced non-small cell lung cancer (NSCLC) with EGFR ex20ins mutation[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Firmonertinib | 99.89% | Firmonertinib (Alflutinib; Furmonertinib) is an orally active, mutant-selective, and highly brain penetrant EGFR inhibitor. Firmonertinib inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Firmonertinib has the potential for the research of cancer diseases, especially advanced non-small cell lung cancer (NSCLC) with EGFR ex20ins mutation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.94
HY-112870AFirmonertinib mesylate -
Similarity Score 0.92
HY-138627AST5902 -
Similarity Score 0.89
HY-138627BAST5902 mesylate -
Similarity Score 0.82
HY-138627ARAST5902 trimesylate (Standard) -
Similarity Score 0.71
HY-15772GOsimertinib (GMP) -
Similarity Score 0.71
HY-137433Befotertinib -
Similarity Score 0.70
HY-15772AOsimertinib mesylate -
Similarity Score 0.68
HY-137433ABefotertinib mesylate -
Similarity Score 0.68
HY-15772S1Osimertinib-13C,d3 -
Explore the MedChemAI to find more analogs
